Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Operating Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Operating Expenses for 3 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • For Q4 2025, Operating Expenses rose 20.06% year-over-year to $21.9 million; the TTM value through Dec 2025 reached $89.8 million, up 32.98%, while the annual FY2025 figure was $89.8 million, 32.99% up from the prior year.
  • Operating Expenses hit $21.9 million in Q4 2025 for Artiva Biotherapeutics, down from $22.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $22.9 million in Q3 2025 and bottomed at $14.3 million in Q4 2023.
  • Average Operating Expenses over 3 years is $18.4 million, with a median of $18.3 million recorded in 2024.
  • Year-over-year, Operating Expenses grew 5.67% in 2024 and then soared 50.38% in 2025.
  • Artiva Biotherapeutics' Operating Expenses stood at $14.3 million in 2023, then rose by 27.56% to $18.3 million in 2024, then grew by 20.06% to $21.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $21.9 million, $22.9 million, and $22.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.